A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer

Sponsor
University College, London
Study ID
NCT03425565
Phase
PHASE2
Status
Completed

Conditions

  • Advanced Cancer
  • Clear Cell Tumor
  • Gynecologic Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    3 weekly cycles of Pembrolizumab administered by IV

Study Details

PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to determine whether treatment with pembrolizumab is effective in patients with advanced clear cell gynaecological cancer.

Key Dates

First listed
Feb 7, 2018
Start date
Feb 18, 2019
Status verified
Sep 2026
Primary completion
Jul 24, 2024
Completion
Sep 18, 2026

Study Design

Enrollment
48 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab

Primary Outcome Measure

Progression Free Survival at 12 Weeks [ Time Frame: 12 weeks ]

Related coverage on Hipa.ai

Related Studies